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Abstract
Background: Diverse mechanisms (increased cell wall thickness, low cross linking, decreased autolysis, etc.) have
been reported for Staphylococcus aureus strains with intermediate vancomycin susceptibility (VISA). This study was
conducted to identify common mechanisms responsible for decreased vancomycin susceptibility in a VISA strain
pair.
Results: Transcriptional profiling of the clinical heterogeneous VISA isolate SA137/93A and its spontaneous
homogeneous mutant strain SA137/93G pointed to an increased capsule production in the strain pair compared to
a susceptible control. Furthermore, transcript quantification of the gene cap5E, which is essential for capsule
biosynthesis, revealed elevated levels in the VISA strains SA137/93A, SA137/93G and Mu50 in comparison with
susceptible strains Reynolds, Newman and SA1450/94. The increased expression was observed in bacteria from
exponential as well as stationary growth phase. However, suppression of type 5 capsule formation by expression of
antisense RNA did not increase vancomycin susceptibility in the VISA strain SA137/93G. Likewise, construction of
inducible mutants of S. aureus Newman or repair of capsule biosynthesis of S. aureus HG001 and S. aureus 1450/94
did not influence resistance to vancomycin. Furthermore, purified type 5 polysaccharide did not protect indicator
strains from the action of vancomycin.
Conclusions: The VISA strain tested in this study displayed an increased production of type 5 capsular
polysaccharide. However, the production of capsule material did not protect strain SA137/93G and three
vancomycin sensitive strains in the presence of vancomycin and thus is not part of the resistance mechanism;
however it may represent a by-product of VISA life style that is often characterized by a high sigma factor B activity.
Background
The phenotype “intermediate vancomycin resistance” in
Staphylococcus aureus (CLSI: MIC=4–8 mg/L in Mueller
Hinton broth (MH)) has been assigned to changes that
lead to alterations in cell wall synthesis and morphology.
Most vancomycin intermediately resistant S. aureus
(VISA) strains are characterized by increased cell wall
thickness as a consequence of activated cell wall biosyn-
thesis and decreased autolysis [1-7]. The mechanism of re-
sistance was shown to be based on an enhanced amount
of free D-Ala-D-Ala termini in the cell wall, which act as
false target sites that keep the vancomycin molecules from
reaching lipid II [2,8]. Many studies have attempted to elu-
cidate the genetic basis of this resistance type, mainly by
comparative transcriptional profiling and full genome se-
quencing (for a review see [9]). Transcriptional profiling
revealed a variety of genes that were differentially ex-
pressed in VISA strains or resistant laboratory mutants
(MIC: ≥ 32 mg/L) in comparison with vancomycin suscep-
tible S. aureus (VSSA). From these results it was postu-
lated that an activated sugar and lipid metabolism and
increased energy are required to generate thicker cell walls
in VISA strains [10-12]. Furthermore, mutations in two
component regulatory systems (yycFG, which was recently
renamed walKR, yvqF/vraSR and graRS) are assumed to
play a central role in adaptation to the antibiotic stress
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prsA [24] and clpP [25].
The clinical methicillin resistant VISA isolate SA137/93A
was isolated from a tracheal secretion and displays hetero-
geneous intermediate vancomycin resistance (hVISA strain,
M I C :2m g / Li nM H ,8m g / Li nb r a i nh e a r ti n f u s i o n( B H I ) ) .
Subculturing in the presence of 6 mg/L vancomycin gener-
ated a mutant with homogeneous intermediate vancomycin
resistance, which showed an MIC value of 16 mg/L in BHI
(4 mg/L in MH) and was designated SA137/93G [4].
Pulsed-field gel electrophoresis (PFGE) profiles, phage typ-
ing and MLST sequencing of the strains showed that they
were members of the Iberian clone (ST247) which was
prevalent in Germany in the early 1990’s under the designa-
tion “Northern German epidemic strain”.B o t hs t r a i n sp o s -
sess a thickened cell wall [4]. The decreased vancomycin
susceptibility of strain SA137/93A is most probably based
on an increased amount of free D-Ala-D-Ala termini in the
cell wall, which is due to decreased crosslinking. Surpris-
ingly, the cell wall cross linking of strain SA137/93G was
within the standard range [4]. As a first step in analysis of
the genetic background of the decreased vancomycin sus-
ceptibility of both strains, the insertion patterns of the
highly mobile insertion element IS256 were compared and
found to be different. Strain SA137/93G is characterized by
an insertion of IS256 into the gene tcaA [26,27] and recon-
stitution of tcaA led to a decrease in vancomycin resistance.
In contrast, strain SA137/93A displays an IS256 insertion
in the promoter region of the essential two-component sys-
tem yycFG (walRK) which leads to an increased expression
of this system [27]. However, although both insertions were
shown to correlate with a decrease in susceptibility to van-
comycin, the difference in the vancomycin resistance level
of the strain pair could be mainly attributed to the disrup-
tion of tcaA in SA137/93G [27]. Furthermore, SA137/93G
carries a deletion which starts at the IS431 element at the
left junction of the SCCmec and covers a chromosomal
fragment that comprises SA0027 to SA0132 [4]. Similar de-
letions starting at the very same bp have been described for
MRSA strains after storage in the laboratory [28]. The ab-
sence of mecA also contributed to the higher vancomycin
resistance of strain SA137/93G [4].
This study was conducted to identify common mecha-
nisms responsible for decreased vancomycin susceptibil-
ity in the hVISA isolate SA137/93A and its homogeneous
resistant derivative SA137/93G. To this end, we com-
pared the transcriptomes of both strains with that of the
closely related vancomycin susceptible MRSA strain
SA1450/94 (MIC: 2 mg/L in BHI). We found that the
genes encoding capsule biosynthesis were the only genes
with higher expression in both VISA strains and there-
fore tested whether the staphylococcal type 5 capsular
polysaccharide (CP5) might be involved in vancomycin
resistance of this strain.
Methods
Bacterial strains, plasmids, growth conditions and
antimicrobial susceptibility testing
Bacterial strains and plasmids are listed in Table 1. S. aureus
strains were cultured in BHI medium, containing 2 g/L glu-
cose (Becton Dickinson GmbH, Heidelberg, Germany) at
37°C with aeration, unless indicated otherwise. For every ex-
periment an overnight culture was diluted 100-fold in fresh
BHI broth and further incubated to an optical density at
600 nm (OD600) of 0.8-1.0 to ensure exponential growth
conditions. Determination of vancomycin MICs was per-
formed following the microdilution method according to
CLSI guidelines except using BHI medium unless indi-
cated otherwise. For E-testing cultures were diluted to an
optical density of 2 McFarland and plated on BHI agar.
Population analysis was carried out as described pre-
viously [29]. Some antisense experiments were performed
on TSA without glucose (TSA-G). Antisense plasmids
were selected with 34 μg/ml chloramphenicol (CM) as
described for the system [30]; otherwise 20 μg/ml of chlor-
amphenicol was employed.
Comparative transcriptomics
For transcriptional profiling, the strains compared were
grown to an OD600 of 0.8-1.0. Preparation of total RNA,
cDNA synthesis and fluorescence labelling as well as
microarray experiments using the sciTRACER S. aureus
N315 full genome chip (Scienion AG, Berlin, Germany)
were performed as described previously [27]. The re-
spective experiments were replicated at least four times
including a dye swap. The microarray data were depos-
ited in the gene expression omnibus (GEO) database at
NCBI under accession number GSE10529.
Comparative genomics
Genomic DNA of the strains SA137/93A, SA137/93G and
SA1450/94 was prepared employing genomic tip 20 col-
umns (Qiagen, Hilden, Germany) according to the ma-
nufacturer’s instructions. Cell lysis was supported by
incubating the cell suspension for 1 h at 37°C in the
presence of 50 mg/L lysostaphin. Genomic DNA (3 μg)
was labelled using the Bioprime DNA labelling system
(Invitrogen, Karlsruhe, Germany) following the instruction
manual. The labelling reaction was performed in the pres-
ence of 0.1 mM cyanine-3’- or cyanine-5’-labelled dCTP
(Perkin Elmer Life Science, Mechelen, Belgium) in ad-
dition to 0.2 mM dCTP, 0.5 mM dATP, 0.5 mM dGTP
and 0.5 mM TTP. The labelled DNA was purified using
the MinElute purification kit (Qiagen) and subsequently
compared by competitive hybridisation employing the
sciTRACER S. aureus N315 full genome chip as described
previously [27]. The experiment was conducted in dupli-
cate including a dye swap.
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The incubation time and media employed for capsule
production are indicated in the figure legends. CP5 pro-
duction was detected by an indirect immunofluores-
cence technique [35]. In brief, bacteria were fixed to
microscope slides with heat and incubated for one hour
with human serum to saturate protein A. The human
serum had been pretreated with protein A deficient
strain Newman (diluted 1:10 in PBS with 0.05% Tween
20) to remove existing S. aureus antibodies from the
serum. Slides were washed and incubated for 1 h at am-
bient temperature with rabbit antiserum specific for
CP5 and diluted 1:200 in PBS with 0.05% Tween 20.
The slides were again washed three times before incuba-
tion with CY3-conjugated goat F(ab)2 fragments raised
to rabbit IgG (Dianova, Hamburg, Germany) diluted
1:500 in PBS with 0.05% Tween 20. In a subsequent
step, the bacteria were stained with 4,6-diamidino-2-
phenylindol (DAPI, 2 mg/L; Sigma-Aldrich, Munich,
Germany) for 5 min at room temperature.
Transcript quantification by real time PCR
Cells of the VISA strains SA137/93A and SA137/93G and
the susceptible controls SA1450/94 and Newman (the CP5
type strain) were harvested from a culture at OD600 0.3, 0.5,
1, 2 and 4–5. RNA preparation and cDNA synthesis were
done as previously described [27]. Experiments were
conducted at least in duplicate for each strain. Transcript
amounts of cap5E were determined in LightCycler (Roche
Diagnostics, Mannheim, Germany) experiments by quanti-
fication relative to the housekeeping gene gyrB employing
external plasmid standards (Table 1) as described pre-
viously [27]. PCR experiments were conducted using the
LightCycler FastStart DNA Master SYBR Green I Kit
(Roche Diagnostics, Mannheim, Germany) according to the
manufacturer’s instructions and the gene specific primer
pairs gyrB-1-RT and gyrB-2-RT [27] and cap5E-1-RT
(CCAGTTGAGGCAGTGAAGACA; NCBI: NC_002745
bp 171655–676) and cap5E-2-RT (CTGATCCTCTTGAA
GCCATCAC; NCBI: NC_002745 bp 171878–899), respect-
ively. The following temperature profile was utilized for
Table 1 Strains and plasmids
Strain/plasmid Relevant genotype or phenotype
a Source/reference
S. aureus strains
SA137/93A Clinical hVISA isolate; MET
r, Northern German epidemic MRSA, MLST sequence
type ST247
[4]
SA137/93G Mutant VISA of SA137/93A; ΔSCCmec (MET
s), ST247 [4,27]
SA137/93G
pCapDvorne
SA137/93G carrying pCapDvorne (CHL
r) This work
Mu50 Clinical VISA isolate [29]
SA1450/94 Northern German epidemic MRSA, Iberian clone, ST247, CP5 positive, VAN
s
control
German reference centre for staphylococci,
Wernigerode
SA1450/94 pCapAre SA1450/94, repair of cap5A This work
SA1450/94 pCU1 SA1450/94, control (empty vector) This work
Newman CP5 positive, VAN
s NCTC8178
Newman-132 pMUTIN integrated into capsule promoter This work
NCTC8325 (RN1) laboratory strain National collection of type cultures
HG001 NCTC8325, repaired in rsbU [31]
HG001 pCap5E HG001 capsule production repaired This work
SG511-Berlin sensitive antibiotic screening strain [32]
RN4220 Restriction negative derivative of NCTC8325, cloning host [33]
Plasmids
pUC19gyrB pUC19, carrying a 560 bp internal fragment of gyrB; external plasmid standard
for real time PCR
This work
pCU1cap5E pCU1 (Augustin), carrying cap5E; external plasmid standard for real time PCR This work
pCapDvorne pEPSA5 (Forsythe) harbouring a cap5D antisense fragment This work
pCapAre pCU1 harbouring cap5A [34]
pCap5E pCU1 harbouring cap5E [34]
pCG132 pMUTIN4 (Vagner 1998) habouring cap5A This work
aAbbreviations: CP, capsular polysaccharides; CHL, chloramphenicol; MET, methicillin; VAN, vancomycin; r, resistant; s, susceptible.
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(20°C/s). 45 cycles of denaturation (95°C; 1 s; 20°C/s),
annealing (55°C; 15 s; 20°C/s), elongation (72°C; 15 s;
20°C/s; single mode). Specificity of the PCR reaction was
verified by melting curve analysis (45°C (10 s; 20°C/s) to
95°C (0.2°C/s), continuous mode) and ethidium bromide
staining on agarose gels. Calculation was done by the
second-derivative maximum method. The quantification
assays were conducted employing RNA prepared from
two independent cultures of each strain.
Antisense experiments
A 166 bp fragment located in the N-terminus of cap5D
was amplified using the primers capD-vorne-166_anti-
for (AAATCTAGAATCTGTGAAATTGCGGCTTT) and
capD-vorne-166_anti-rev (AAAGAATTCTGCTGAAATA
TGATGCGATATG) with Phusion DNA polymerase
(New England Biolabs, Frankfurt, Germany) and ligated to
the vector pEPSA5 [30] using the XbaIa n dEcoRI restric-
tion sites. The ligation assay was transformed into E. coli
JM83 by electroporation, the recombinant plasmid was
shuttled into S. aureus RN4220 by electroporation [36]
and subsequently transduced into S. aureus SA137/93G
by phage transduction using bacteriophage 80α [37]. For
expression of antisense RNA, the cultures were grown in
LB (lysogeny broth)/CM34 or other media as indicated
[30] and were divided for addition of 50 mM xylose to
one of the cultures. Sequencing confirmed that pEPSA5
does not contain the cre sequence, which would inhibit
transcription in the presence of glucose.
Complementation of cap5E
The defect in Cap5E in strains of the NCTC 8325 lineage
(the M134R exchange that leads to inactivation of the pro-
tein) was complemented using cap5E on pCU1 as de-
scribed in [34]. The DNA fragment harbouring cap5E (bp
3394–5448 in NCBI acc. nr. U81973, [34]) was amplified by
PCR employing the primers cap5Eforward (GCTTCTAGA
CTAGTTTTGCAGGCAGG) and cap5Ereverse (GTCGA
GCTCGTTAAATCTGCTTTCAA) from S. aureus New-
man DNA, ligated into pCU1 and after subcloning in E. coli
and S. aureus RN4220 the recombinant plasmid was intro-
duced into S. aureus HG001 [31].
Generation of a conditional capsule mutant
In gram-positive bacteria, pMUTIN4 is an integrative vec-
tor that places the downstream genes under control of a
Pspac promoter [38]. The cap5A gene was amplified using
the primers EcoRIcap431-for (GGGGGAATTCTAAGGGA
GGTAAATAATGG) and BamHcap1431-rev (ACACGGAT
CCATTAAGCTTGATAGTCCA), ligated with the restric-
ted (EcoRI, BamHI) pMUTIN4 plasmid and transformed
into E. coli. The resulting plasmid (pCG132) was verified
by sequencing and electroporated into S. aureus strain
RN4220. Since pMUTIN4 does not have a gram-positive
origin of replication, all clones had gone through a single
crossover event, which inserted the vector into the gen-
ome and placed the cap5A gene under the control of the
IPTG-inducible Pspac promoter. The integrated plasmid
was then transduced into strain Newman using Φ11 lysates.
Mutants were verified by PCR using the oligonucleotides
P5spac (TACATCCAGAACAACCTCTG) and capArev
(GACTTTAACTGCTGTACCGTCTGCT) and PFGE.
Extraction of capsular polysaccharides (CP)
For extraction of crude capsule extract, staphylococci were
plated onto Columbia blood agar plates that had been
supplemented with 50 mM NaCl. After 24 h of incubation
at 37°C, the bacteria were harvested by suspension in PBS
buffer. The CP was detached from the cells by autoclaving
at 120°C for 1 h and the cell debris was removed by centri-
fugation. The supernatant was passed through a cellulose
acetate filter (pore size 0.45 μm). Cell wall teichoic acid was
removed by treatment with 50 mM NaIO4 for 72 h at room
temperature in the dark [39]. The crude extract was then
washed with PBS buffer by ultrafiltration on a YM10 mem-
brane (Millipore, Schwalbach, Germany) or employing
Vivaspin 6 columns (exclusion volume of 3 kDa) (Sartorius,
Göttingen Germany). These extracts were then added to
MIC determinations in MH medium using S. aureus
NCTC 8325 and S. aureus SG511 as indicator strains. In
order to test for contaminating nucleic acids, the extracts
were digested with DNase and RNAse [40] and tested
again. Crude capsule extract from S. aureus NCTC 8325
which cannot produce a capsule because of the point muta-
tion in Cap5E and PBS buffer served as negative controls in
these experiments. Purified CP5 was obtained as described
in [41].
Sequencing of the promoter region of the CP5
biosynthesis gene cluster
A 735 bp DNA segment comprising the promoter region
of the CP5 biosynthesis gene cluster was amplified using a
standard PCR protocol and the primer pair (AGCTCG
CATTTGAAGATCAATGT) and (CCTCTTGTGCCATA
AACTGAGG)(bp166966–166988andbp167586–167607,
NCBI: NC_002745). The product was purified (QIAquick
Gel Extraction Kit, Qiagen, Hilden, Germany) and se-
quenced (Sequiserve, Vaterstetten, Germany).
Detection of the cap5 gene cluster in the VISA strains
was performed using primers cap5-9864 (GTACGAAGCG
TTTTGATAGTT) and cap5-9332 (GAAAGTGAACGAT
TAGTAGAA) that flank the type-specific sequences of
cap5I and cap5J in S. aureus [42].
The insertion of IS256 in cap5A in S. aureus SA1450/94
was complemented by reconstituting cap5A on the plasmid
pCapAre, exactly as described in [34]. The fragment was
amplified employing genomic DNA of S. aureus SA137/93G
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GAGCTCGCATTTGAA) and pCapAreconrev (CCAAT
GATTAAGCTTGATAGTCC). These primers harbour the
natural cleavage sites that had been used for complementa-
tion previously [34].
Results and discussion
Comparative transcriptomics
The clinical VISA isolate SA137/93A and the type strain
of the Iberian clone in Germany (‘Northern German
epidemic strain’) SA1450/94 showed identical PFGE pat-
terns [43] and MLST types (ST247). In order to further
confirm that SA1450/94 is a suitable control strain,
chromosomal DNA of SA137/93A was competitively
hybridised to that of SA1450/94 and SA137/93G, re-
spectively. The microarray results showed that all ORFs
present in the VISA strain SA137/93A were also present
in strain SA1450/94. In addition, the competitive hybrid-
isation precisely reflected the deletion in the mutant
SA137/93G [4].
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throughout the growth curve of hVISA SA137/93A (filled square), VISA SA137/93G (filled triangle), VSSA Newman (filled circle) and VSSA SA1450/
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6 copies of the housekeeping gene gyrB. b) Transcript amounts of cap5E of VSSA strains
(R: Reynolds*, N: Newman, 14: SA1450/94) and VISA strains (A: SA137/93A*, G: SA137/93G*, Mu: Mu50) at OD600=1 and OD600=4–5 indicated as
copy number per 10
6 copies of gyrB. * Error bars are not visible at OD600=1 because of minimal data variations.
Jansen et al. BMC Microbiology 2013, 13:65 Page 5 of 12
http://www.biomedcentral.com/1471-2180/13/65Comparative transcriptomics of the hVISA isolate
SA137/93A and SA1450/94 revealed that there were only
15 genes showing a higher expression level in the hVISA
strain (2- to12-fold; see Additional file 1: gene expression
data.pdf, Additional file 1: Table S1). The yycFGHI-operon
[27] and three genes of the type 5/8 capsule biosynthesis
gene cluster (capB, capC, capE), which showed a 4- to 5-
fold higher expression, were among the ten genes with a
known function in Additional file 1: Table S1. The rela-
tively low number of regulated genes may be due to the
fact that the strain shows a heterogeneous phenotype, i.e.,
only a subpopulation of the culture displays high resist-
ance to vancomycin. Similar results were obtained with
the JH series of mutants; here JH1 to JH5 did not show
any alterations in gene expression, although resistance had
increased [44,45], therefore, this observation was not
surprising.
As expected, the transcription profile of the VISA
strain SA137/93G differed more strikingly from that of
SA1450/94. A total of 124 genes showed at least a two-
fold change in strain SA137/93G (2- to 13.7-fold; see
Additional file 1: gene expression data.pdf, Additional
file 1: Table S2) compared to SA1450/94. 30.6% of these
genes encoded hypothetical proteins. Figure 1 shows the
percentage of regulated genes in the different functional
gene classes. Only one category of genes, “adaptation to
atypical conditions”, which comprises genes encoding
capsule biosynthesis enzymes, chaperones, heat and cold
shock proteins and the clp protease, was overrepresented
among the genes showing higher transcription levels.
The 16 genes of the capsular biosynthesis gene cluster
capABCDEFGHIJKLMNOP were - on average - six fold
up-regulated. Additionally, a more than twofold increase
in transcript amounts was found for the gene encoding
AlsS, which is involved in formation of acetoine from
pyruvate and influences the regulation of autolysis [46],
the urease operon and two ORFs of the ica gene cluster.
All of the above mentioned genes have also been found
to be up-regulated under mildly acidic conditions [47].
Since some of the genes with lower expression levels in
strain SA137/93G were also down-regulated under
acidic conditions, part of the expression profile might be
the consequence of differences in the pH decrease of the
glucose-containing BHI medium that was used for culti-
vating the strains. This hypothesis is supported by the
finding of Nelson et al. [48] indicating that an impaired
catabolism of acetate seems to be typical for some VISA
strains and might result in the up-regulation of urease,
which supplies ammonium ions that neutralize the de-
crease in pH caused by the formation of acids [49]. In
addition, the capsule gene cluster, alsS and SA2262,
SA2367 as well as SA2403 are members of the sigB
regulon and might indicate an increased SigB activity
which has been shown to contribute towards glycopep-
tide resistance [50]. A more than twofold decrease in ex-
pression was observed for 80 genes (2- to 13.7-fold) in
the VISA strain SA137/93G in comparison with the sus-
ceptible control. In summary, an increased transcription
of genes involved in capsule biosynthesis was the only ex-
pression pattern that was common to both VISA strains
in comparison to the VSSA strain.
Cap5E transcript quantification by real time PCR
The cap5 and the cap8 loci are allelic, each comprising
16 genes (capA-P) that are transcribed in one orientation
with 12 of the 16 genes being nearly identical. The four
genes in the central region of the cluster are type-specific
and show little homology [51]. The presence of the type
5 gene cluster in the VISA strains and SA1450/94 had
been indicated by the microarray results and was con-
firmed by PCR. In S. aureus, capsule production occurs
primarily in the late log and post-exponential growth
phase. It had previously been shown that S. aureus CPs
are not detectable before the late log growth phase, 2 h
after the transcript increase in the mid log phase [52,53].
For exact quantitative analysis of expression of the CP
biosynthetic enzymes and to obtain further insights into
capsule production in different growth phases, the tran-
scription level of the essential capsule gene cap5E [34]
was determined by real time PCR. Figure 2a shows the
expression rate of cap5E throughout the growth curve of
the VISA strains and the controls. The expression
Figure 3 Comparison of CP5 production in a VISA and two VSSA strains. CP5 was labelled by immunofluorescence (CY3, green). As a
control, all cells were stained using DAPI (blue). Cells were grown for 6 h in LB at 37°C. a) VISA SA137/93G; b) control strain SA1450/94; c) S.
aureus Newman.
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A strong increase of capsule expression occurred in the
post-exponential growth phase after the culture reached
an optical density of 2 (Figure 2a) in VSSA and VISA
strains, and the basal expression level in strain SA137/93A
and SA137/93G was already elevated during the early
growth phase. Furthermore, an increase of cap5E gene
transcription could be observed in the stationary growth
phase in the VISA strains, with a 2- to 3-fold increased ex-
pression level at an OD600 of about 5. A lower transcrip-
tion in VSSA strains in exponential and stationary phase
could be confirmed when strain Reynolds and Newman
were included into the measurements (Figure 2b). These
findings were consistent with the primary microarray-
based data of this study and expression data of S. aureus
Mu50 [10].
The CPs of Klebsiella pneumoniae were found to con-
tribute to resistance to cationic defensins, lactoferrin, pro-
tamine sulfate and polymyxin B, and in this context, the
capsule was assumed to protect bacteria by limiting the
interaction of the antimicrobial peptides with the surface
[54]. Later, similar results were obtained with polysaccha-
rides from Streptococcus pneumoniae and alginate from
Pseudomonas aeruginosa [55]. A possible role of CPs in
vancomycin resistance has repeatedly been discussed in
the literature. Boyle-Vavra et al. found that susceptible
passage revertants of the CP5 producing VISA isolates MI,
NJ and PC were no longer CP typable, while passaging in
presence of vancomycin retained the CP phenotype [56].
Besides, comparative expression profiling experiments on
VISA isolates Mu50, MI, JH9 and their respective suscep-
tible parent or mutant strains showed that some (but not
necessarily all) of the genes of the type 5 capsule were
more highly expressed in the VISA strains [10,45]. En-
hanced capsule production in other VISA was also
reported [57] and deletion of the yabJ-spoVG operon af-
fected glycopeptide susceptibility and capsule production
in S. aureus simultaneously [50]. Taken together, these
findings encouraged us to further investigate the role of
CPs in vancomycin resistance.
Detection of the capsule by immunofluorescence
Production of CP5 was analysed by immunofluorescent la-
belling of cells of SA137/93G and the susceptible strains
SA1450/94 and Newman after 6 h of incubation in LB.
The results revealed that the VISA strain produced higher
amounts of CP5 than SA1450/94 and S. aureus Newman
(Figure 3).
Sequence of the capsule promoter of VISA strains and
SA1450/94
In order to detect possible changes in the promoter of the
capsule gene cluster that might be responsible for an ele-
vated expression in the VISA strains, a region covering
400 bp upstream of cap5A was sequenced. The complete
sequences were identical to that published for S. aureus
COL (ST250), which is a close relative of the Iberian
strain, and S. aureus RF122. The promoter sequence of
the cap5 gene cluster and the inverted repeats that consti-
tute the operator [58,59] were identical to that of the first
seven published genomes. Unexpectedly, the control strain
SA1450/94 showed an insertion of IS256 into the first
gene of the capsule gene cluster cap5A1. The IS element
was located 50 bp downstream of the ATG start codon
and oriented in an antisense direction. Cap5A1 encodes a
membrane protein that is part of the protein kinase
Cap5A1/Cap5B2, which is needed for phosphorylation of
Cap5O [60]. In spite of this, in in vitro experiments
Cap5A1 is not essential for activation of Cap5O since a
paralogue of Cap5A1, Cap5A2 is encoded by SA2457 and
able to activate the kinase subunit Cap5B2 [60]; this is also
demonstrated by the fact that SA1450/94 was able to pro-
duce capsule, albeit at low levels, in overnight cultures
(data not shown).
The effect of capsule on vancomycin resistance in VISA
Initial attempts to knock out capsule production in
the VISA strains resulted in mutants that could not be
complemented because they harboured background mu-
tations in regulatory genes that are necessary for cap-
sule production and influence glycopeptide susceptibility
Figure 4 Suppression of capsule formation by expression of cap5D-antisense RNA. CP5 was labelled by immunofluorescence (CY3, green),
the cells were stained using DAPI (blue). Cells were grown for 6 h in LB at 37°C. a) S. aureus SA137/93G (control); b) S. aureus SA137/93G
harbouring pCapDvorne in the absence of xylose and c) grown in the presence of 50 mM xylose.
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http://www.biomedcentral.com/1471-2180/13/65(rsbU, agr), e.g., inactivation of rsbU led to an increase in
vancomycin susceptibility in our isolates even if capsule
biosynthesis had been reconstituted. Therefore, we chose
an antisense approach. An N-terminal 166 bp fragment of
cap5D was ligated to pEPSA5 in antisense direction and
transformed into S. aureus 137/93G. We chose another
region than that described in [30] since antisense RNA ex-
pression from this fragment had exerted growth-inhibitory
effects. Capsule formation was analyzed by immunofluor-
escence in the absence and presence of 50 mM xylose in
different media (LB, BHI and CYPG [61]) after 6 h of in-
cubation. Figure 4 shows that after only 6 h of incubation,
capsule formation in the wildtype SA137/93G is relatively
strong even in LB (Figure 4c), and that the capsule forma-
tion is somewhat decreased in the presence of the plasmid
even in the absence of xylose (Figure 4b). Addition of
50 mM xylose (but not 12.5 mM) led to a full repression
of capsule biosynthesis (Figure 4c) in all tested media with
the exception of a few cells that had obviously been able
to eliminate the plasmid.
In MIC determinations in LB/CM 34, no significant dif-
ference in vancomycin resistance was observed after ex-
pression of antisense RNA in S. aureus SA137/93G. The
value of 1.5±0.4 mg/L vancomycin obtained for encapsu-
lated strains grown in the absence of xylose was lowered to
1.3±0.3 mg/L vancomycin for capsule-free cells incubated
i nt h ep r e s e n c eo fx y l o s e .
Intermediate vancomycin susceptibility of VISA strains is
most easily demonstrated in population analyses on BHI,
which is the medium that yields the highest vancomycin
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Figure 5 Population analyses of different strains in the presence or absence of capsule. a) S. aureus SA137/93G harbouring pCapDvorne
grown on BHI agar in the absence of xylose (capsule; □ ) or in the presence of xylose (no capsule; ■ ); b) S. aureus SA137/93G harbouring
pCapDvorne grown on TSA without glucose in the absence (□ ) or in the presence of xylose (■ ); c) S. aureus HG001 (□ ) and S. aureus HG001
harbouring pcap5E (■ ) which leads to reconstitution of capsule biosynthesis on BHI agar; d) S. aureus Newman harbouring an insertion of
pMUTIN4 in the capsule promoter grown on MH agar in the absence (□ ) and the presence (■ ) of 1 mM IPTG.
Figure 6 Repair of capsule formation in S. aureus HG001. CP5 was labelled by immunofluorescence (CY3, green), the cells were stained using
DAPI (blue). Cells were grown in TSB medium overnight at 37°C. a) S. aureus HG001 (control); b) S. aureus HG001 pCap5E, in which capsule
production has been reconstituted.
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Again there was no difference in the population analyses
of clones grown in the absence or presence of xylose
(Figure 5a). Experiments in TSA-G (TSA without glucose)
yielded similar results (Figure 5b).
The effect of the capsule on vancomycin resistance in
VSSA
In addition to the VISA strain, the effect of the capsule on
vancomycin resistance in three vancomycin susceptible
strains producing CP5 was investigated. All strains of the
RN1 (NCTC 8325) lineage harbour a mutation in cap5E
that leads to inactivation of capsule biosynthesis. Further-
more a deletion in rsbU leads to a very low activity of sigma
B which however is needed for the efficient transcription of
the capsule biosynthetic genes [50]. As described in [34],
capsule production was reconstituted into S. aureus HG001
(rsbU repaired) by introduction of a plasmid carrying a
cap5E gene amplified from S. aureus Newman (Figure 6).
Again the population showed a heterogeneous pheno-
type in immunofluorescence experiments. However, in
population analyses no increase in resistance against vanco-
mycin could be detected (Figure 5c).
An S. aureus Newman clone with the capsule promoter
under control of Pspac was capsule negative in the absence
of inducer, but heterogeneous capsule production could be
achieved by addition of IPTG to media that did not contain
glucose, e.g., MH (Figure 7). In population analyses with
these cells, no significant difference in vancomycin resist-
ance on MH agar was visible (Figure 5d).
As capsule production in SA1450/94 might be impaired
by the insertion of IS256 described above, it was attempted
to reconstitute CP5 production. In S. aureus Newman in-
sertion of Tn916 into cap5A1 could be repaired by comple-
mentation of cap5A1 in trans [34]. Therefore, a similar
construct (pCapAre) was introduced into SA1450/94,
Figure 7 Induction of capsule production by IPTG in S. aureus Newman-132. CP5 was labelled by immunofluorescence (CY3, green), the
cells were stained using DAPI (blue). Cells were grown for 6 h in MH medium at 37°C. a) S. aureus Newman (control) b) S. aureus Newman in the
presence of 0.5 mM IPTG; c) S. aureus Newman-132 harbouring pMUTIN4 in the capsule promoter in the absence of IPTG and d) S. aureus
Newman-132 harbouring pMUTIN4 in the capsule promoter after induction with IPTG.
Figure 8 Capsule production of different S. aureus SA1450/94 clones. CP5 was labelled by immunofluorescence (CY3, green), the cells were
stained using DAPI (blue). Cells were grown for 6 hours in BHI medium at 37°C. a) S. aureus SA1450/94 harbouring pCapAre, which has
reconstituted capsule production; b) SA1450/94 (control) and c) SA1450/94 harbouring pCU1 (vector control).
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ent strain (Figure 8). However, full capsule production was
not achieved and the vancomycin MIC of the clone
remained unchanged compared to SA1450/94.
Furthermore, a capsule knockout mutant of strain
Reynolds had previously been tested against vanco-
mycin, and no differences in susceptibility to vanco-
mycin were recorded [62]. Population analyses in our
laboratory confirmed this result (data not shown).
Effect of capsule material on the susceptibility of
staphylococci to vancomycin
In order to test whether capsule material is able to interact
with or bind to vancomycin, crude capsular material was
prepared from S. aureus 137/93G and S. aureus NCTC
8325 (negative control; as shown in Figure 6 for S. aureus
HG001, the strains of this lineage do not produce a capsule
unless cap5E is repaired). Cell wall teichoic acid that might
contaminate the extracts was removed by periodate oxida-
tion. The material was added to MIC determinations using
S. aureus NCTC8325 and S. aureus SG511 as indicator
strains in MH medium. There was no significant difference
in the MIC values between the extract containing capsular
material and the controls for S. aureus SG511, however
a small effect (0.7 mg/L increase in the MIC) was visible
with S. aureus NCTC8325 and the extract of S. aureus
SA137/93G. The test was repeated 8 times with two differ-
ent preparations of the capsular material; an additional
DNase and RNase digest did not influence the result. While
we cannot explain this difference, the fact that no increase
in the MIC was visible with the more susceptible indicator
strain strongly indicated that the type 5 capsular material
did not neutralise the effect of vancomycin in this assay.
The experiment was repeated with purified CP5 (32 μg/ml)
in MIC determinations in MH medium. Both indicator
strains did not show any alterations in susceptibility to
vancomycin, which confirmed the above result.
Conclusions
Although an increased transcription of the capsular gene
cluster has been observed for several VISA strains, the type
5 capsule does not seem to play a significant role in the re-
sistance mechanism of S. aureus 137/93G. It may therefore
be assumed that - at least in the strain investigated here -
an increased or uniform transcription of the capsule gene
cluster is a phenomenon that accompanies vancomycin re-
sistance, perhaps a by-product of a relatively high SigB ac-
tivity in S. aureus 137/93G, indicated by the intense yellow
colour of this strain, that might contribute to glycopeptide
resistance [50] or an overflow from an activated cell wall
metabolism [1], rather than being the cause for vancomycin
resistance.
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